Levact

Bendamustine Hydrochloride, the active ingredient in Levact, is a alkylating agent (nitrogen mustard) presented as a solution for injection for intravenous use. It treats chronic lymphocytic leukemia and non‑Hodgkin lymphoma in adult patients and is indicated for the management of these hematologic malignancies under the supervision of a qualified healthcare professional.

GNH USA supplies Levact as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, ensuring quality and regulatory compliance for the European market and beyond.

Levact (bendamustine hydrochloride) is used in the treatment of hematologic cancers, particularly those involving B‑cell malignancies.

Chronic lymphocytic leukemia: achieves disease control and prolongs progression‑free survival. Non‑Hodgkin lymphoma: induces tumor regression and contributes to overall response rates. Indolent non‑Hodgkin lymphoma (e.g., follicular lymphoma): provides durable remission and improves quality of life. Mantle cell lymphoma (relapsed): offers response in patients with prior therapy.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring during or after infusion. - Fatigue: generalized tiredness that may affect daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet count leading to bleeding tendencies. - Anemia: decreased red blood cells causing weakness. - Fever: may indicate infection or inflammatory response.

Serious or Rare Side Effects: - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Severe infections: opportunistic or bacterial infections requiring prompt treatment. - Pulmonary toxicity: interstitial pneumonitis or respiratory distress. - Allergic reactions: hypersensitivity including rash, pruritus, or anaphylaxis. - Secondary malignancies: rare development of new cancers after treatment. - Hepatotoxicity: liver enzyme elevation or dysfunction.

Before initiating therapy, patients should be evaluated for baseline blood counts and organ function.

Monitor blood counts: perform regular CBC to detect cytopenias. Assess renal and hepatic function: adjust use in impairment. Avoid use in active infection: treat infections before therapy. Pregnancy and lactation: contraindicated unless benefits outweigh risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Bendamustine may interact with other agents that affect bone marrow or drug metabolism.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: can exacerbate cytopenias. - Strong CYP3A4 inhibitors (e.g., azole antifungals): may increase bendamustine exposure. - Live vaccines: risk of infection due to immunosuppression. - Radiotherapy: additive toxicity to bone marrow. - Monoclonal antibodies targeting CD20: overlapping immunosuppressive effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Anticoagulants (e.g., warfarin): increased bleeding risk with thrombocytopenia. - NSAIDs: potential for gastrointestinal irritation. - Allopurinol: may affect uric acid metabolism. - Proton pump inhibitors: possible alteration of drug absorption.